drugset / Trial / NCT07069569

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

NCT07069569

Phase 2 Recruiting 200 enrolled Ausper Biopharma Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.

Timeline

Start
2025-06-08
Primary completion
2027-07-15
Completion
2028-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AHB-137 Antisense oligonucleotide Other
Subject Hepatitis B vaccine Vaccine
Subject Peginterferon alfa-2a Protein / enzyme biologic